155P PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel–cisplatin chemotherapy

Abstract

QuantStudio® 3D Digital PCR System (ABI, USA). For realtime PCR was used a thermal cycler Rotor-Gene 6000 (Qiagen, Germany), PCR was performed in a final volume of 20ml, reaction mixture contained 70mM Tris-HCl (pH 8.8), 16.6mM ammonium sulphate, 0.01% Tween-20, 2mM magnesium chloride, 200 nM of each dNTP, 500 nM of primers, 250 nM of fluorescent probe, 1000 nM of blocking probe, 1.5 units Taq-DNA polymerase. Probes used in fluorescent dyes – FAM and VIC, quenchers – BHQ-1 and BHQ-2. Sets of oligonucleotides were designed and produced by “Testgen Ltd” (Russia). Results: By comparing of the EGFR mutations status in plasma and tumor samples concordance was 88.7% [95% CI 85%, 92%], sensitivity – 83.3% [95% CI 76%, 90%], specificity – 100%, PPV – 100%. The analytical sensitivity of dPCR was 0.1% Analytical specificity – 99.5%. Analytical sensitivity for real-time PCR was 0.2%, the analytical specificity – 99.7%. Conclusions: Digital PCR has demonstrated the best analytical sensitivity, wherein concordance with real-time PCR was 100%. Legal entity responsible for the study: Kazan Clinical Oncology Center, Kazan, RU Funding: Kazan Clinical Oncology Center, Kazan, RU Disclosure: All authors have declared no conflicts of interest.